BOTULINUM TOXIN FORMULATION

摘要

Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.

主权项

1. A method for treating a disease or condition in a human patient by administering to the patient a pharmaceutical composition comprising a botulinum neurotoxin, albumin and a viscous carrier for the botulinum neurotoxin, wherein the viscous carrier comprises a cross-linked hyaluronic acid having a molecular weight ranging from about 10,000 daltons to about 200,000 daltons, a crosslinking density ranging from about 5% to about 10%, present in an range from about 1% to about 4% (w/v) of the pharmaceutical composition, wherein the pharmaceutical composition having a viscosity range from about 100 cps to about 1,000 cps at a sheer rate 0.1/second at 25° C.; and wherein the patient experiences significantly fewer complications due to the botulinum toxin than occur upon administration of a botulinum toxin containing pharmaceutical composition which does not comprise a viscous carrier.